Disease · HP_0001257
Spasticity
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Spasticity. Diseases, record HP_0001257. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001257
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Spasticity
- Open Targets ID
- HP_0001257
- Other names
- Involuntary muscle stiffness, contraction, or spasm, Muscle spasticity, Muscular spasticity
- Highest stage of its drugs
- Approval, for 5 of its 27 drugs, from DailyMed, FDA and PMDA
Source Open Targets
Drugs27
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BACLOFEN | CHEMBL701 | Small molecule | Approval | DailyMed and FDA | 64 | 8 | 8 | Drugs and targets |
| INCOBOTULINUMTOXINA | CHEMBL2108035 | Approval | PMDA | 9 | 8 | 8 | Drugs and targets | |
| TIZANIDINE HYDROCHLORIDE | CHEMBL1200329 | Small molecule | Approval | DailyMed | 5 | 1 | 1 | Drugs and targets |
| CYCLOBENZAPRINE HYDROCHLORIDE | CHEMBL1200636 | Small molecule | Approval | DailyMed | 2 | 0 | 0 | Drugs and targets |
| DANTROLENE SODIUM | CHEMBL928 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| ONABOTULINUMTOXINA | CHEMBL1201574 | Phase 3 | ClinicalTrials.gov | 28 | 28 | 18 | Drugs and targets | |
| BOTULINUM TOXIN TYPE A | CHEMBL4297862 | Protein | Phase 3 | ClinicalTrials.gov | 17 | 17 | 16 | Drugs and targets |
| NABIXIMOLS | CHEMBL3833333 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 8 | Drugs and targets |
| ARBACLOFEN | CHEMBL301742 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| DRONABINOL | CHEMBL465 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 3 | Drugs and targets |
1 to 10 of 27
See all 27 drugsTargets76
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SNAP25 | Synaptosomal-associated protein 25 | 5 | Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | Approval | https://conductscience.org/library/genes/6616 | Drugs and targets |
| CNR1 | Cannabinoid receptor 1 | 3 | Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| GABBR1 | GABA-B receptor | 3 | GABA-B receptor agonist | Approval | https://conductscience.org/library/genes/2550 | Drugs and targets |
| GABBR2 | GABA-B receptor | 3 | GABA-B receptor agonist | Approval | https://conductscience.org/library/genes/9568 | Drugs and targets |
| ADRA2A | Adrenergic receptor alpha-2 | 2 | Adrenergic receptor alpha-2 agonist | Approval | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha-2 | 2 | Adrenergic receptor alpha-2 agonist | Approval | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor alpha-2 | 2 | Adrenergic receptor alpha-2 agonist | Approval | https://conductscience.org/library/genes/152 | Drugs and targets |
| CACNA1B | Voltage-dependent N-type calcium channel subunit alpha-1B | 1 | Voltage-gated N-type calcium channel alpha-1B subunit blocker | Phase 2 | https://conductscience.org/library/genes/774 | Drugs and targets |
| DDC | Aromatic-L-amino-acid decarboxylase | 1 | DOPA decarboxylase inhibitor | Phase 1 | https://conductscience.org/library/genes/1644 | Drugs and targets |
| DRD3 | D(3) dopamine receptor | 1 | Dopamine D3 receptor agonist | Phase 1 | https://conductscience.org/library/genes/1814 | Drugs and targets |
1 to 10 of 76
See all 76 targetsTrials80
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 15 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00681538 | A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS) | Phase 3 | 572 | 2011-12-07 | Spasticity, Multiple Sclerosis | NABIXIMOLS | Its record names the disease | ClinicalTrials.gov |
| NCT03290131 | A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS | Phase 3 | 536 | 2022-07-15 | Multiple Sclerosis, Spasticity, Muscle | ARBACLOFEN | Its record names the disease | ClinicalTrials.gov |
| NCT01606137 | A Study of the Long-term Safety of Sativex Use | Phase 3 | 507 | 2012-08-23 | Multiple Sclerosis, Spasticity, Pain | CANNABIDIOL, DRONABINOL, NABIXIMOLS | Its record names the disease | ClinicalTrials.gov |
| NCT01575054 | BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity | Phase 3 | 468 | 2016-02-01 | Muscle Spasticity | ONABOTULINUMTOXINA, SODIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01603641 | BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity | Phase 3 | 370 | 2019-08-21 | Pediatrics, Muscle Spasticity, Cerebral Palsy | ONABOTULINUMTOXINA | Its record names the disease | ClinicalTrials.gov |
| NCT01905683 | Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy | Phase 3 | 370 | 2017-10-27 | Lower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy | INCOBOTULINUMTOXINA | Its record names the disease | ClinicalTrials.gov |
| NCT02002884 | Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy | Phase 3 | 351 | 2020-08-03 | Cerebral Palsy, Spasticity | INCOBOTULINUMTOXINA | Its record names the disease | ClinicalTrials.gov |
| NCT03319732 | A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS | Phase 3 | 323 | 2022-07-15 | Multiple Sclerosis, Spasticity, Muscle | ARBACLOFEN | Its record names the disease | ClinicalTrials.gov |
| NCT01392300 | Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke | Phase 3 | 317 | 2016-02-11 | Post-stroke Spasticity of the Upper Limb | INCOBOTULINUMTOXINA | Its record names the disease | ClinicalTrials.gov |
| NCT01893411 | Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy | Phase 3 | 311 | 2017-05-12 | Lower Limb Spasticity Due to Cerebral Palsy | INCOBOTULINUMTOXINA | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 80
See all 80 trialsComparisons in its trials41
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Botulinum Toxin Type A vs Normal Saline (Placebo): serious adverse events | 10 of 231 | 9 of 233 | 464 | NCT01575054 | Trial comparisons |
| Double-blind IncobotulinumtoxinA (Xeomin) (400 Units) vs Double-blind Placebo Comparator: Response Rates on the Ashworth Scale at Week 4 Calculated for the Muscle Group Flexed Wrist | 102 of 171 | 31 of 88 | 259 | NCT01392300 | Trial comparisons |
| Double-blind IncobotulinumtoxinA (Xeomin) (400 Units) vs Double-blind Placebo Comparator: Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Flexed Elbow | 85 of 171 | 28 of 88 | 259 | NCT01392300 | Trial comparisons |
| Double-blind IncobotulinumtoxinA (Xeomin) (400 Units) vs Double-blind Placebo Comparator: Response Rates on the Ashworth Scale at Week 8 Calculated for the Primary Target Clinical Pattern | 104 of 171 | 34 of 88 | 259 | NCT01392300 | Trial comparisons |
| Double-blind IncobotulinumtoxinA (Xeomin) (400 Units) vs Double-blind Placebo Comparator: Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Thumb-in-palm | 52 of 171 | 23 of 88 | 259 | NCT01392300 | Trial comparisons |
| Double-blind IncobotulinumtoxinA (Xeomin) (400 Units) vs Double-blind Placebo Comparator: Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Flexed Wrist | 90 of 171 | 33 of 88 | 259 | NCT01392300 | Trial comparisons |
| Double-blind IncobotulinumtoxinA (Xeomin) (400 Units) vs Double-blind Placebo Comparator: Response Rates on the Ashworth Scale at Week 12 Calculated for the Muscle Group Clenched Fist | 49 of 171 | 19 of 88 | 259 | NCT01392300 | Trial comparisons |
| Double-blind IncobotulinumtoxinA (Xeomin) (400 Units) vs Double-blind Placebo Comparator: Response Rates on the Ashworth Scale at Week 4 Calculated for the Muscle Group Thumb-in-palm | 56 of 171 | 21 of 88 | 259 | NCT01392300 | Trial comparisons |
| Double-blind IncobotulinumtoxinA (Xeomin) (400 Units) vs Double-blind Placebo Comparator: Response Rates on the Ashworth Scale at Week 12 Calculated for the Muscle Group Flexed Elbow | 52 of 171 | 21 of 88 | 259 | NCT01392300 | Trial comparisons |
| Double-blind IncobotulinumtoxinA (Xeomin) (400 Units) vs Double-blind Placebo Comparator: Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Clenched Fist | 82 of 171 | 27 of 88 | 259 | NCT01392300 | Trial comparisons |
1 to 10 of 41
See all 41 comparisons in its trialsPapers from its trials53
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0001257
GET https://conductscience.org/api/diseases/v1/HP_0001257/drugs?page=2